Latest:
Diagnostic Challenges and Clinical Updates in Soft Tissue Sarcomas
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Gaudenz Danuser, PhD
Latest:
Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma
Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.
Gauri R. Varadhachary, MD
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Gennedy Bratslavsky, MD
Latest:
Dr. Bratslavsky on the Evaluation and Management of Kidney Cancer
Gennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.
Geoffrey Hugo, PhD
Latest:
Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer Center
The Department of
Radiation Oncology
at Virginia Commonwealth
University
Massey Cancer Center has
long been at the forefront
worldwide in the development
of various radiation
therapy technologies that
are now considered standard
and have become widely available.
Geoffrey Lindeman, MD
Latest:
Dr. Lindeman on Rationale for a Phase Ib Trial of Venetoclax and Tamoxifen in Breast Cancer
Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.
Geoffrey R. Oxnard, MD
Latest:
How Complementary Roles in Clinic and Industry Illuminate Avenues for Patient-Centered Cancer Care: With D. Ross Camidge, MD, PhD; and Geoff Oxnard, MD
Drs. Camidge and Oxnard discuss novel EGFR inhibitors, the role of precision medicine in early cancer detection, and balancing clinical and industry roles.
Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital
Latest:
RP1: An Emerging Intratumoral Therapy
Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.
Geoffrey Uy, MD
Latest:
Dr. Uy on Therapy Selection in Acute Myeloid Leukemia
Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).
Geoffrey Y. Ku, MD
Latest:
Dr. Ku on the Efficacy of Zanidatamab Plus Chemotherapy in HER2+ Gastroesophageal Adenocarcinoma
Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.
George D. Demetri, MD
Latest:
Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers
George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.